National Pharmaceutical Council President and CEO Dan Leonard in a recent write up published on Pharmacy Times outlines some key findings of research by NPC and CEVR on coverage decisions by insurers.
A joint study published by the pair in 2018, Leonard writes, found that “insurance coverage and reimbursement for specialty medications varied substantially, with only 15.9% of drug coverage policies consistent across the largest United States commercial health plans.”
“Comprehensive, and consistent evaluation of evidence is needed, and inclusion of real-world evidence is critical, to ensure patient appropriate and evidence-based access to specialty medicines,” he writes.
To read the full write up, click here.
